Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

November 27, 2018

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval larotrectinib in NTRK-positive cancers.

November 21, 2018

Charles M. Rudin, MD, PhD, reflects on the latest developments in small cell lung cancer.

November 20, 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient rectal cancer.

November 20, 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses challenges in the treatment of patients with metastatic urothelial carcinoma.

November 20, 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the use of prostate-specific membrane antigen (PSMA)-targeted imaging in patients with metastatic castration-resistant prostate cancer.

November 16, 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination approaches garnering interest in endometrial cancer.

November 15, 2018

Alexander E. Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of tepotinib and gefitinib (Iressa) in patients with MET-positive EGFR-mutant non–small cell lung cancer (NSCLC).

November 10, 2018

Jonathan E. Rosenberg, MD, discusses the extended follow-up of the CheckMate-032 study, as well as the future of immunotherapy in urothelial carcinoma.

November 02, 2018

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

October 30, 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer.

October 29, 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses induction chemotherapy in patients with mismatch repair deficient rectal cancer.

October 27, 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses immunogenicity in endometrial cancer.

October 23, 2018

Andrea V. Barrio, MD, FACS, breast surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with HER2-positive breast cancer.

October 01, 2018

Like clinicians elsewhere, investigators from the University of Colorado, Denver, struggled not only to predict the likelihood that a particular patient would do well with surgery alone but also to convey their estimates in terms that patients would understand.

September 29, 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.

September 28, 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.

September 27, 2018

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

September 14, 2018

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape for patients with multiple myeloma.

August 29, 2018

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

August 16, 2018

Alexander E. Drilon, MD, discusses the data with LOXO-292 thus far and the promise for this agent in patients with RET alterations.